Advanced glycation end products and its soluble receptor in AOSD pathogenic role

碩士 === 國立中興大學 === 生命科學院碩士在職專班 === 101 === Adult onset Still’s disease (AOSD) is a chronic inflammatory disease characterized by fever of unknown origin, arthritis, and skin rash. However the etiopathogenesis of AOSD remains unclear. Studies have shown that the levels of advanced glycation end produc...

Full description

Bibliographic Details
Main Authors: Yen- Ching Wu, 吳燕晴
Other Authors: Der- Yuan Chen
Format: Others
Language:zh-TW
Published: 2013
Online Access:http://ndltd.ncl.edu.tw/handle/64966087533341905520
id ndltd-TW-101NCHU5105002
record_format oai_dc
spelling ndltd-TW-101NCHU51050022017-10-29T04:34:16Z http://ndltd.ncl.edu.tw/handle/64966087533341905520 Advanced glycation end products and its soluble receptor in AOSD pathogenic role 糖化終產物及其可溶性接受器在成人型史迪兒氏症致病機轉之角色 Yen- Ching Wu 吳燕晴 碩士 國立中興大學 生命科學院碩士在職專班 101 Adult onset Still’s disease (AOSD) is a chronic inflammatory disease characterized by fever of unknown origin, arthritis, and skin rash. However the etiopathogenesis of AOSD remains unclear. Studies have shown that the levels of advanced glycation end products (AGEs) were associated with chronic inflammation, and were positively correlated with disease duration of systemic lupus erythematosus (SLE). Although AOSD is also an inflammatory disease, there is no any data regarding AGEs in this disease. In order to explore the relationship between AOSD and AGEs as well as their receptors, we enrolled 52 patients with AOSD, 36 patients with SLE, and 16 healthy volunteers, and used the enzyme-linked immunosorbent assay (ELISA) to detect plasma (or serum) levels of AGEs and their soluble receptors for advanced glycation end products (sRAGE). Our results showed plasma (or serum) AGEs levels were significantly higher in patients with active AOSD compared with healthy controls (mean± SEM; 19.47± 1.84 µg/ ml vs. 8.45± 0.97μg/ ml; p < 0.001). Plasma (or serum) AGEs levels were also significantly higher in patients with active AOSD compared with inactive AOSD (mean± SEM; 7.52± 0.57μg/ ml; p < 0.001). Whereas, plasma (or serum) sRAGE levels were significantly lower in patients with active AOSD compared with healthy controls (mean± SEM; 650.7± 59.0 pg/ml vs.1129.7± 98.7 pg/ ml; p< 0.001). Plasma (or serum) sRAGE levels were lower in patients with active AOSD compared with inactive AOSD (mean± SEM; 985.3± 106.9 pg/ ml; p < 0.05). Similarly, plasma (or serum) AGEs levels were higher and sRAGE levels were lower in patients with active SLE compared with inactive SLE or healthy control. Plasma (or serum) AGEs levels were also positively correlated with activity markers of AOSD including a activity score (r =0.836 ; p < 0.001)、ferritin ( r =0.372;p <0.05)、ESR(r =0.413;p <0.005)、CRP( r =0.396;p <0.005).In conclusion our results suggested that AGEs and sRAGE could be useful markers for clinical physician to monitor disease activity of AOSD. Der- Yuan Chen 陳得源 2013 學位論文 ; thesis 47 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 國立中興大學 === 生命科學院碩士在職專班 === 101 === Adult onset Still’s disease (AOSD) is a chronic inflammatory disease characterized by fever of unknown origin, arthritis, and skin rash. However the etiopathogenesis of AOSD remains unclear. Studies have shown that the levels of advanced glycation end products (AGEs) were associated with chronic inflammation, and were positively correlated with disease duration of systemic lupus erythematosus (SLE). Although AOSD is also an inflammatory disease, there is no any data regarding AGEs in this disease. In order to explore the relationship between AOSD and AGEs as well as their receptors, we enrolled 52 patients with AOSD, 36 patients with SLE, and 16 healthy volunteers, and used the enzyme-linked immunosorbent assay (ELISA) to detect plasma (or serum) levels of AGEs and their soluble receptors for advanced glycation end products (sRAGE). Our results showed plasma (or serum) AGEs levels were significantly higher in patients with active AOSD compared with healthy controls (mean± SEM; 19.47± 1.84 µg/ ml vs. 8.45± 0.97μg/ ml; p < 0.001). Plasma (or serum) AGEs levels were also significantly higher in patients with active AOSD compared with inactive AOSD (mean± SEM; 7.52± 0.57μg/ ml; p < 0.001). Whereas, plasma (or serum) sRAGE levels were significantly lower in patients with active AOSD compared with healthy controls (mean± SEM; 650.7± 59.0 pg/ml vs.1129.7± 98.7 pg/ ml; p< 0.001). Plasma (or serum) sRAGE levels were lower in patients with active AOSD compared with inactive AOSD (mean± SEM; 985.3± 106.9 pg/ ml; p < 0.05). Similarly, plasma (or serum) AGEs levels were higher and sRAGE levels were lower in patients with active SLE compared with inactive SLE or healthy control. Plasma (or serum) AGEs levels were also positively correlated with activity markers of AOSD including a activity score (r =0.836 ; p < 0.001)、ferritin ( r =0.372;p <0.05)、ESR(r =0.413;p <0.005)、CRP( r =0.396;p <0.005).In conclusion our results suggested that AGEs and sRAGE could be useful markers for clinical physician to monitor disease activity of AOSD.
author2 Der- Yuan Chen
author_facet Der- Yuan Chen
Yen- Ching Wu
吳燕晴
author Yen- Ching Wu
吳燕晴
spellingShingle Yen- Ching Wu
吳燕晴
Advanced glycation end products and its soluble receptor in AOSD pathogenic role
author_sort Yen- Ching Wu
title Advanced glycation end products and its soluble receptor in AOSD pathogenic role
title_short Advanced glycation end products and its soluble receptor in AOSD pathogenic role
title_full Advanced glycation end products and its soluble receptor in AOSD pathogenic role
title_fullStr Advanced glycation end products and its soluble receptor in AOSD pathogenic role
title_full_unstemmed Advanced glycation end products and its soluble receptor in AOSD pathogenic role
title_sort advanced glycation end products and its soluble receptor in aosd pathogenic role
publishDate 2013
url http://ndltd.ncl.edu.tw/handle/64966087533341905520
work_keys_str_mv AT yenchingwu advancedglycationendproductsanditssolublereceptorinaosdpathogenicrole
AT wúyànqíng advancedglycationendproductsanditssolublereceptorinaosdpathogenicrole
AT yenchingwu tánghuàzhōngchǎnwùjíqíkěróngxìngjiēshòuqìzàichéngrénxíngshǐdíérshìzhèngzhìbìngjīzhuǎnzhījiǎosè
AT wúyànqíng tánghuàzhōngchǎnwùjíqíkěróngxìngjiēshòuqìzàichéngrénxíngshǐdíérshìzhèngzhìbìngjīzhuǎnzhījiǎosè
_version_ 1718557292835635200